These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

567 related articles for article (PubMed ID: 34514991)

  • 1. Rationality, Efficacy, Tolerability of Empagliflozin Plus Linagliptin Combination for the Management of Type 2 Diabetes Mellitus: A Systematic Review of Randomized Controlled Trials and Observational Studies.
    Chenchula S; Varthya SB; Padmavathi R
    Curr Diabetes Rev; 2022; 18(4):e100921196392. PubMed ID: 34514991
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Linagliptin as add-on to empagliflozin and metformin in patients with type 2 diabetes: Two 24-week randomized, double-blind, double-dummy, parallel-group trials.
    Tinahones FJ; Gallwitz B; Nordaby M; Götz S; Maldonado-Lutomirsky M; Woerle HJ; Broedl UC
    Diabetes Obes Metab; 2017 Feb; 19(2):266-274. PubMed ID: 27762093
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Empagliflozin as Add-on Therapy in Patients With Type 2 Diabetes Inadequately Controlled With Linagliptin and Metformin: A 24-Week Randomized, Double-Blind, Parallel-Group Trial.
    Søfteland E; Meier JJ; Vangen B; Toorawa R; Maldonado-Lutomirsky M; Broedl UC
    Diabetes Care; 2017 Feb; 40(2):201-209. PubMed ID: 27913576
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combination of empagliflozin and linagliptin as second-line therapy in subjects with type 2 diabetes inadequately controlled on metformin.
    DeFronzo RA; Lewin A; Patel S; Liu D; Kaste R; Woerle HJ; Broedl UC
    Diabetes Care; 2015 Mar; 38(3):384-93. PubMed ID: 25583754
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Empagliflozin/linagliptin single-pill combination therapy for patients with type 2 diabetes mellitus.
    Jain RK
    Expert Opin Pharmacother; 2017 Apr; 18(6):545-549. PubMed ID: 28375658
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fixed-dose combination of empagliflozin and linagliptin for the treatment of patients with type 2 diabetes mellitus: A systematic review and meta-analysis.
    Katsiki N; Ofori-Asenso R; Ferrannini E; Mazidi M
    Diabetes Obes Metab; 2020 Jun; 22(6):1001-1005. PubMed ID: 32020696
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Empagliflozin as add-on to linagliptin in a fixed-dose combination in Japanese patients with type 2 diabetes: Glycaemic efficacy and safety profile in a 52-week, randomized, placebo-controlled trial.
    Kawamori R; Haneda M; Suzaki K; Cheng G; Shiki K; Miyamoto Y; Solimando F; Lee C; Lee J; George J
    Diabetes Obes Metab; 2018 Sep; 20(9):2200-2209. PubMed ID: 29766636
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rationale, design and baseline characteristics of a 4-year (208-week) phase III trial of empagliflozin, an SGLT2 inhibitor, versus glimepiride as add-on to metformin in patients with type 2 diabetes mellitus with insufficient glycemic control.
    Ridderstråle M; Svaerd R; Zeller C; Kim G; Woerle HJ; Broedl UC;
    Cardiovasc Diabetol; 2013 Sep; 12():129. PubMed ID: 24007456
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Single-pill combination therapy for type 2 diabetes mellitus: linagliptin plus empagliflozin.
    Aronson R
    Curr Med Res Opin; 2015 May; 31(5):901-11. PubMed ID: 25775379
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A safety evaluation of empagliflozin plus linagliptin for treating type 2 diabetes.
    Gallwitz B
    Expert Opin Drug Saf; 2017 Dec; 16(12):1399-1405. PubMed ID: 28934557
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety and tolerability of empagliflozin and linagliptin combination therapy in patients with type 2 diabetes mellitus: a pooled analysis of data from five randomized, controlled clinical trials.
    Watada H; Yamauchi T; Yamamoto F; Taniguchi A; Yarush L; Heilmann C; Yasui A
    Expert Opin Drug Saf; 2020 Sep; 19(9):1193-1202. PubMed ID: 32552153
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Machine Learning to Identify Predictors of Glycemic Control in Type 2 Diabetes: An Analysis of Target HbA1c Reduction Using Empagliflozin/Linagliptin Data.
    Del Parigi A; Tang W; Liu D; Lee C; Pratley R
    Pharmaceut Med; 2019 Jun; 33(3):209-217. PubMed ID: 31933292
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Empagliflozin/linagliptin single-tablet combination: first-in-class treatment option.
    Woo V
    Int J Clin Pract; 2015 Dec; 69(12):1427-37. PubMed ID: 26303997
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of efficacy and safety of empagliflozin vs linagliptin added to premixed insulin in patients with uncontrolled type 2 diabetes: A randomized, open-label study.
    Liu SC; Lee CC; Chuang SM; Sun FJ; Zeng YH
    Diabetes Metab; 2021 May; 47(3):101184. PubMed ID: 32827752
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Triple fixed-dose combination empagliflozin, linagliptin, and metformin for patients with type 2 diabetes.
    Lingvay I; Beetz N; Sennewald R; Schuler-Metz A; Bertulis J; Loley C; Lang B; Lippert C; Lee J; Manning LS; Terada D
    Postgrad Med; 2020 May; 132(4):337-345. PubMed ID: 32366156
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety and Tolerability of Combinations of Empagliflozin and Linagliptin in Patients with Type 2 Diabetes: Pooled Data from Two Randomized Controlled Trials.
    DeFronzo RA; Lee C; Kohler S
    Adv Ther; 2018 Jul; 35(7):1009-1022. PubMed ID: 29949041
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetic drug evaluation of empagliflozin plus linagliptin for the treatment of type 2 diabetes.
    Rizos CV; Filippatos TD; Elisaf MS
    Expert Opin Drug Metab Toxicol; 2018 Jan; 14(1):117-125. PubMed ID: 29241374
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Empagliflozin and linagliptin combination therapy for treatment of patients with type 2 diabetes mellitus.
    Triplitt C; Solis-Herrera C; Cersosimo E; Abdul-Ghani M; Defronzo RA
    Expert Opin Pharmacother; 2015; 16(18):2819-33. PubMed ID: 26583910
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Empagliflozin as Add-on Therapy to Pioglitazone With or Without Metformin in Patients With Type 2 Diabetes Mellitus.
    Kovacs CS; Seshiah V; Merker L; Christiansen AV; Roux F; Salsali A; Kim G; Stella P; Woerle HJ; Broedl UC;
    Clin Ther; 2015 Aug; 37(8):1773-88.e1. PubMed ID: 26138864
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety of linagliptin in subjects with long-standing type 2 diabetes mellitus (>10 years): evidence from pooled data of randomized, double-blind, placebo-controlled, phase III trials.
    Lajara R; Aguilar R; Hehnke U; Woerle HJ; von Eynatten M
    Clin Ther; 2014 Nov; 36(11):1595-605. PubMed ID: 25236917
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 29.